Corporate Banner
Satellite Banner
Technology Networks Header
Friday, October 31, 2014
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
First Atlas of Body Clock Gene Expression in Mammals Informs Timing of Drug Delivery
Penn Medicine study has implications for 100 top-selling US drugs, half of which target daily-oscillating genes.
Single Gene Mutation Eliminates ISG15
Single gene links susceptibility to rare infections with predisposition to autoimmune disease.
New Technique Yields Drug, Biomedical Test Results in One Minute
Slug flow microextraction makes it possible to quickly detect the presence of drugs or to monitor certain medical conditions using only a single drop of blood or urine.
New Clues For Early Colorectal Cancer Detection
Study identifies new biomarkers which could help detect colorectal cancer.
New 'Lab-on-a-Chip' Could Revolutionize Early Diagnosis of Cancer
Faster result times, reduced costs, minimal sample demands and better sensitivity of analysis.
Dramatic Response And Resistance To Cancer Drug Traced
Sequencing reveals why thyroid tumor responded to, and eventually resisted, treatment.
Personalized Ovarian Cancer Vaccines
UConn Researchers have found a new way to identify protein mutations in cancer cells.
NanoString, Brigham and Women’s Hospital Collaborate
Research collaboration to accelerate translation of genomic discoveries into clinical diagnostics in oncology.
Colorful Nanoprobes Make A Simple Test
Gold nanoparticles linked to single-stranded DNA create a simple but versatile genetic testing kit.
How Gene Expression Affects Facial Expressions
Researchers from USC have demonstrated how a mutation in TBX1 causes facial deformities associated with DiGeorge Syndrome.
Scroll Up
Scroll Down
Return
Multi Center Validation of a New Molecular Diagnostic Assay for Accurate and Rapid Screening of JAK2 V617F Mutation
Fabienne Hermitte, CSO, Ipsogen, speaking at the Molecular Diagnostics World Congress 2007
Date Posted: Monday, May 19, 2008
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



IPSOGEN Expands its U.S. Presence through Licensing Agreement with Quest Diagnostics
Ipsogen entered a non-exclusive license agreement with Quest for the use of the JAK2 V617F mutation in Quest Diagnostic's laboratory developed tests.
Tuesday, October 07, 2008
IPSOGEN Expands its U.S. Presence Through Licensing Agreement with Quest Diagnostics
Ipsogen SA, a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and leukemia, today announced a non-exclusive license agreement with Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, for the use of the JAK2 V617F mutation in Quest Diagnostic's laboratory developed tests.
Monday, October 06, 2008
Ipsogen Launches MapQuant Dx™ Genomic Grade Test to Analyze Chemotherapy Results
The Company expects that by improving the accuracy of tumor grading, the test could spare tens of thousands chemotherapy treatments per year.
Monday, June 02, 2008
Ipsogen Announces Three Studies at the American Society of Clinical Oncology Meeting
The results from the studies extend the utility of the Genomic Grade index for predicting response to chemotherapy in breast cancer.
Monday, May 26, 2008
IPSOGEN Licenses the Genomic Grade™ to Improve Breast Cancer Diagnosis & Treatment Decision
IPSOGEN signed a license agreement with Universite Libre de Bruxelles (ULB), Belgium for the worldwide and exclusive rights on the Genomic Grade™.
Monday, January 28, 2008
Ipsogen Reports Recommendation of JAK2V617F Mutation Screening in WHO 2008 Criteria and Point-of-Care Diagnostic Algorithms
The 2008 revision of the WHO document on the classification of CMPDs has incorporated new information on the molecular pathogenesis of BCR–ABL negative myeloproliferative disorders including the screening for JAK2V617F mutation.
Tuesday, January 22, 2008
IPSOGEN Grants Labcorp License for Leukemia Molecular Diagnostic Assay in USA
IPSOGEN grants LabCorp non-exclusive rights to offer an assay for the diagnosis of a group of leukemias caused by JAK2 gene variations.
Tuesday, September 11, 2007
Ipsogen Grants Exclusive License to Warnex to Market a Leukemia Molecular Diagnostic Service in Canada
Ipsogen grants Warnex exclusive rights to market a service for the diagnosis and the classification of a group of leukemias.
Thursday, August 16, 2007
Ipsogen Presents Breast Cancer Biomarker Results at the EBCC 5
These results concern the identification on 323 patient samples.
Monday, February 27, 2006
 
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv